# A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

> **NCT05433584** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 780 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Tirzepatide
- **DRUG:** Antihyperglycemic medication

## Key facts

- **NCT ID:** NCT05433584
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-01
- **Primary completion:** 2025-10-21
- **Final completion:** 2027-11
- **Target enrollment:** 780 (ESTIMATED)
- **Last updated:** 2025-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05433584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05433584, "A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05433584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*